CN106237032A - A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof - Google Patents
A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof Download PDFInfo
- Publication number
- CN106237032A CN106237032A CN201610776067.3A CN201610776067A CN106237032A CN 106237032 A CN106237032 A CN 106237032A CN 201610776067 A CN201610776067 A CN 201610776067A CN 106237032 A CN106237032 A CN 106237032A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- colon cancer
- traditional chinese
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 30
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002131 composite material Substances 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241000827798 Hemerocallis citrina Species 0.000 claims abstract description 19
- 241001057584 Myrrha Species 0.000 claims abstract description 19
- 241000522620 Scorpio Species 0.000 claims abstract description 19
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 19
- 239000009490 scorpio Substances 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000007788 liquid Substances 0.000 claims description 36
- 238000000605 extraction Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000006185 dispersion Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 4
- 208000014081 polyp of colon Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 206010034647 Peristalsis visible Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 208000022534 visible peristalsis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of compound traditional Chinese medicine composite treating colon cancer, it is mainly by made by the crude drug of following weight portion: 5 fluorouracil 0.05 part, 10 20 parts of Hemerocallis citrina Baroni, Herba Verbenae 10 20 parts, Myrrha 15 35 parts, Radix Angelicae Sinensis 5 15 parts, the Cortex Eucommiae 5 25 parts, Herba Epimedii 10 30 parts, the Radix Aucklandiae 10 30 parts, Carapax Trionycis 5 25 parts, Scorpio 15 25 parts, Radix Tripterygii Wilfordii 10 20 parts, TPGS 28 parts, phosphatidase 20 30 parts.Present invention also offers the preparation method of the compound traditional Chinese medicine composite of described treatment colon cancer.Relative to prior art, the compound traditional Chinese medicine composite of the treatment colon cancer of gained of the present invention, low cost, technique is simple, can not only improve treatment colon cancer curative effect further, moreover it is possible to significantly reduce the side effect of chemical medicine treatment.
Description
Technical field
The present invention relates to a kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof, belong to Chinese medicine preparation technology
Field.
Background technology
Tumor is one of major disease of current serious threat human life safety, no matter both at home and abroad, has a large amount of every year
Patient dead because suffering from tumor.Colon cancer is the common malignant tumor of digestive tract betiding colon site, is apt to occur in rectum
With sigmoid colon intersection, the highest with 40～50 years old age group sickness rate, the ratio of men and women is 2～3:1.Sickness rate accounts for gastrointestinal tract and swells
The 3rd of tumor.Colon cancer is mainly adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma.General form is polypoid, ulcer type etc..Colon cancer
Can go in ring along intestinal wall and develop, indulge footpath along intestinal tube and spread up and down or infiltrate to intestinal wall deep layer, except through lymphatic vessel, blood flow transfer and local
Outside infringement, also can be to intraperitoneal plantation or along suture, cut sides diffusion transfer.Patients with chronic colitis, polyp of colon patient, man
Property overweight people wait as Susceptible population.It is main the most relevant with higher fatty acid and low cellulose diet that colon cancer is fallen ill.The chronic inflammation of colon
Disease makes the incidence rate of intestinal cancer higher than population.The person that has polyp of colon, colon cancer incidence rate is 5 times without polyp of colon person.Family
Race's property multiple polyp intestinal tumor, the incidence rate of canceration is higher.Inherited genetic factors may also assist in the morbidity of colon cancer.Can not have in early days
Having any symptom, middle and advanced stage can behave as abdominal distention, dyspepsia, then occurs that bowl evacuation habit changes, stomachache, and mucus is just or glutinous blood
Just.Tumor is festered, is lost blood, after toxin absorption, often occur anemia, low grade fever, weak, become thin, the symptom such as lower limbs edema.As abdomen occurs
Swollen, stomachache, constipation or can not defecation, health check-up is shown in that there is a tenderness abdominal tympanites, visible peristalsis visible intestinal peristalsis, local, and auscultation news and borborygmus, prompting may
Infull property or complete intestinal obstruction occur.If tumor and nethike embrane, surrounding tissue infiltration adhesion, form irregular enclosed mass.Late period can
The tumor diffusions turn at a distance such as liver, the Lung metastases signs such as jaundice, seroperitoneum, edema, cachexia, supraclavicular lymph nodes enlargement occur
The performance moved.
At present, Drug therapy colon cancer is a kind of important approach, but the medicine of existing treatment colon cancer, great majority
For chemical medicine, therapeutic effect is not satisfactory, and side effect is big.
Summary of the invention
Goal of the invention: in order to overcome the deficiencies in the prior art, the present invention provide a kind of treat colon cancer answer
Side's Chinese medicine composition and preparation method thereof.
Technical scheme: for achieving the above object, the invention provides a kind of compound traditional Chinese medicine composite treating colon cancer, its
Main by made by the crude drug of following weight portion:
5-fluorouracil 0.05 part, Hemerocallis citrina Baroni 10-20 part, Herba Verbenae 10-20 part, Myrrha 15-35 part, Radix Angelicae Sinensis 5-15 part,
Cortex Eucommiae 5-25 part, Herba Epimedii 10-30 part, Radix Aucklandiae 10-30 part, Carapax Trionycis 5-25 part, Scorpio 15-25 part,
Radix Tripterygii Wilfordii 10-20 part, TPGS 2-8 part, phosphatidase 2 0-30 part.
As preferably, the compound traditional Chinese medicine composite of described treatment colon cancer is mainly by the crude drug institute of following weight portion
Make:
5-fluorouracil 0.05 part, Hemerocallis citrina Baroni 12-18 part, Herba Verbenae 12-18 part, Myrrha 20-30 part, Radix Angelicae Sinensis 8-12 part,
Cortex Eucommiae 10-20 part, Herba Epimedii 15-25 part, Radix Aucklandiae 15-25 part, Carapax Trionycis 10-20 part, Scorpio 18-22 part,
Radix Tripterygii Wilfordii 12-18 part, TPGS 4-6 part, phosphatidase 2 2-28 part.
Preferred as another kind, the compound traditional Chinese medicine composite of described treatment colon cancer mainly former by following weight portion
Made by material medicine:
5-fluorouracil 0.05 part, 15 parts of Hemerocallis citrina Baroni, Herba Verbenae 15 parts, Myrrha 25 parts, Radix Angelicae Sinensis 10 parts,
The Cortex Eucommiae 15 parts, Herba Epimedii 20 parts, the Radix Aucklandiae 20 parts, Carapax Trionycis 15 parts, Scorpio 20 parts,
Radix Tripterygii Wilfordii 15 parts, TPGS 5 parts, phosphatidase 25 parts.
Present invention also offers the preparation method of the compound traditional Chinese medicine composite of described treatment colon cancer, comprise the following steps:
(1) weighing Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, the 60-80% ethanol adding 6-10 times of body returns
Stream extracts 3 times, and each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 8-12 times of volume of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 2000-4000r/min, ice bath disperses 2-4 minute, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 1000-2000r/min stirs
5-10 minute, concentrate, dry, pulverize, standby, obtain described Chinese medicine composition.
As preferably, described Chinese medicine composition conventionally makes solid preparation.
Further preferably, described solid preparation is granule, powder, tablet, pill or capsule.
Beneficial effect: relative to prior art, the treatment colon cancer of gained of the present invention compound traditional Chinese medicine composite, cost
Low, technique is simple, can not only improve treatment colon cancer curative effect further, moreover it is possible to significantly reduce the side effect of chemical medicine treatment.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further described.
Embodiment 1
Prescription:
5-fluorouracil 0.05 part, 10 parts of Hemerocallis citrina Baroni, Herba Verbenae 10 parts, Myrrha 15 parts, Radix Angelicae Sinensis 5 parts,
The Cortex Eucommiae 5 parts, Herba Epimedii 10 parts, the Radix Aucklandiae 10 parts, Carapax Trionycis 5 parts, Scorpio 15 parts,
Radix Tripterygii Wilfordii 10 parts, TPGS 2 parts, phosphatidase 20 part.
Preparation technology:
(1) weigh Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, add 80% alcohol reflux 3 of 6 times of bodies
Secondary, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 8 times of volumes of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 2000r/min, ice bath disperses 4 minutes, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 1000r/min stirs 10 points
Clock, concentrates, dry, pulverize, standby, obtains described Chinese medicine composition.
Described Chinese medicine composition conventionally makes granule.
Embodiment 2
Prescription:
5-fluorouracil 0.05 part, 20 parts of Hemerocallis citrina Baroni, Herba Verbenae 20 parts, Myrrha 35 parts, Radix Angelicae Sinensis 15 parts,
The Cortex Eucommiae 25 parts, Herba Epimedii 30 parts, the Radix Aucklandiae 30 parts, Carapax Trionycis 25 parts, Scorpio 25 parts,
Radix Tripterygii Wilfordii 20 parts, TPGS 8 parts, phosphatidase 30 part.
Preparation technology:
(1) weigh Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, add 60% alcohol reflux of 10 times of bodies
3 times, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 12 times of volumes of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 4000r/min, ice bath disperses 2 minutes, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 2000r/min stirs 5 points
Clock, concentrates, dry, pulverize, standby, obtains described Chinese medicine composition.
Described Chinese medicine composition conventionally makes powder.
Embodiment 3
Prescription:
5-fluorouracil 0.05 part, 15 parts of Hemerocallis citrina Baroni, Herba Verbenae 15 parts, Myrrha 25 parts, Radix Angelicae Sinensis 10 parts,
The Cortex Eucommiae 15 parts, Herba Epimedii 20 parts, the Radix Aucklandiae 20 parts, Carapax Trionycis 15 parts, Scorpio 20 parts,
Radix Tripterygii Wilfordii 15 parts, TPGS 5 parts, phosphatidase 25 parts.
Preparation technology:
(1) weigh Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, add 70% alcohol reflux 3 of 8 times of bodies
Secondary, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 10 times of volumes of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 3000r/min, ice bath disperses 3 minutes, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 1500r/min stirs 8 points
Clock, concentrates, dry, pulverize, standby, obtains described Chinese medicine composition.
Described Chinese medicine composition conventionally makes tablet.
Embodiment 4
Prescription:
5-fluorouracil 0.05 part, 12 parts of Hemerocallis citrina Baroni, Herba Verbenae 12 parts, Myrrha 20 parts, Radix Angelicae Sinensis 8 parts,
The Cortex Eucommiae 10 parts, Herba Epimedii 15 parts, the Radix Aucklandiae 15 parts, Carapax Trionycis 10 parts, Scorpio 18 parts,
Radix Tripterygii Wilfordii 12 parts, TPGS 4 parts, phosphatidase 22 parts.
Preparation technology:
(1) weigh Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, add 75% alcohol reflux 3 of 7 times of bodies
Secondary, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 9 times of volumes of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 3000r/min, ice bath disperses 3 minutes, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 1000r/min stirs 8 points
Clock, concentrates, dry, pulverize, standby, obtains described Chinese medicine composition.
Described Chinese medicine composition conventionally makes pill.
Embodiment 5
Prescription:
5-fluorouracil 0.05 part, 18 parts of Hemerocallis citrina Baroni, Herba Verbenae 18 parts, Myrrha 30 parts, Radix Angelicae Sinensis 12 parts,
The Cortex Eucommiae 20 parts, Herba Epimedii 25 parts, the Radix Aucklandiae 25 parts, Carapax Trionycis 20 parts, Scorpio 22 parts,
Radix Tripterygii Wilfordii 18 parts, TPGS 6 parts, phosphatidase 28 parts.
Preparation technology:
(1) weigh Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, add 65% alcohol reflux 3 of 9 times of bodies
Secondary, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtained extracting solution A；
(2) Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii are weighed in proportion, residue after the alcohol extraction with step (1) gained
Merge, the water reflux, extract, of 11 times of volumes of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) taking 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stir
Mixing limit to be added dropwise in distilled water, then under the conditions of 3000r/min, ice bath disperses 3 minutes, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 2000r/min stirs 8 points
Clock, concentrates, dry, pulverize, standby, obtains described Chinese medicine composition.
Described Chinese medicine composition conventionally makes capsule.
The experimental study of experimental example compound traditional Chinese medicine composite of the present invention treatment colon cancer
By prior art--azoxymethane associating dextran sulfate sodium Salt treatment mouse junction cancer makes mouse Colon
Cancer model, is randomly divided into 6 groups, often group 20, be set to blank group, compare 1 group, compare 2 groups, treat 1 group, treat 2 groups and
Treat 3 groups；
Blank group does not carry out any Drug therapy；
Compare 1 group in feedstuff, to add step (3) gained dispersion liquid in the embodiment of the present invention 3 treat；
Compareing 2 groups and add by the embodiment of the present invention 3 in feedstuff, removal step (3) dispersion liquid products obtained therefrom is treated；
Treat 1 group, treat 2 groups and the treatment 3 groups use embodiment of the present invention 3,4 and 5 products obtained therefrom in feedstuff.
Other management methods are the most identical, after treating 2 weeks, record each group of mortality rate and survival mice body weight, and dissect survival
Mice, investigates each group of tumor relative weight relative to blank group tumor.
Can be obtained by table 1 below result, compare more blank group, the survival mice tumor weight treating 1 group, 2 groups and 3 groups is the most notable
Reduce, and compare 1 group and decrease with 2 groups of tumor weights of comparison, but reduce the most notable.
Secondly, comparing more blank group, the survival mice body weight treating 1 group, 2 groups and 3 groups all dramatically increases, and compares 1 group
Increased with compareing 2 groups of Mouse Weights, but be to increase inconspicuous.Mouse Weight increases, and shows to treat side effect little, mice
Life quality improves.
Finally, compared with two matched groups, the mortality rate treating 1 group, 2 groups and 3 groups all significantly reduces, and compares 1 group
Although decreasing with compareing 2 groups of mortality rates, but reduce the most notable.Mortality rate reduces, and on the one hand shows that therapeutic effect is bright
Aobvious, on the other hand also indicate that treatment side effect is low, mouse survival quality is high.
Therapeutic outcome respectively organized by table 1
Note: compared with blank group, * P < 0.05；Compared with matched group, #P < 0.05.
Claims (6)
1. the compound traditional Chinese medicine composite treating colon cancer, it is characterised in that it is mainly by the crude drug institute of following weight portion
Make:
5-fluorouracil 0.05 part, Hemerocallis citrina Baroni 10-20 part, Herba Verbenae 10-20 part, Myrrha 15-35 part, Radix Angelicae Sinensis 5-15 part,
Cortex Eucommiae 5-25 part, Herba Epimedii 10-30 part, Radix Aucklandiae 10-30 part, Carapax Trionycis 5-25 part, Scorpio 15-25 part,
Radix Tripterygii Wilfordii 10-20 part, TPGS 2-8 part, phosphatidase 2 0-30 part.
The compound traditional Chinese medicine composite for the treatment of colon cancer the most according to claim 1, it is characterised in that it is mainly by as follows
Made by the crude drug of weight portion:
5-fluorouracil 0.05 part, Hemerocallis citrina Baroni 12-18 part, Herba Verbenae 12-18 part, Myrrha 20-30 part, Radix Angelicae Sinensis 8-12 part,
Cortex Eucommiae 10-20 part, Herba Epimedii 15-25 part, Radix Aucklandiae 15-25 part, Carapax Trionycis 10-20 part, Scorpio 18-22 part,
Radix Tripterygii Wilfordii 12-18 part, TPGS 4-6 part, phosphatidase 2 2-28 part.
The compound traditional Chinese medicine composite for the treatment of colon cancer the most according to claim 1, it is characterised in that it is mainly by as follows
Made by the crude drug of weight portion:
5-fluorouracil 0.05 part, 15 parts of Hemerocallis citrina Baroni, Herba Verbenae 15 parts, Myrrha 25 parts, Radix Angelicae Sinensis 10 parts,
The Cortex Eucommiae 15 parts, Herba Epimedii 20 parts, the Radix Aucklandiae 20 parts, Carapax Trionycis 15 parts, Scorpio 20 parts,
Radix Tripterygii Wilfordii 15 parts, TPGS 5 parts, phosphatidase 25 parts.
4. treat the preparation method of the compound traditional Chinese medicine composite of colon cancer described in any one of claim 1-3, it is characterised in that bag
Include following steps:
(1) weighing Hemerocallis citrina Baroni, Herba Verbenae, Myrrha, Radix Angelicae Sinensis and the Cortex Eucommiae in proportion, the 60-80% alcohol reflux adding 6-10 times of body carries
Taking 3 times, each 2 hours, united extraction liquid, recovery ethanol, to without alcohol taste, obtains extracting solution A；
(2) weighing Herba Epimedii, the Radix Aucklandiae, Carapax Trionycis, Scorpio and Radix Tripterygii Wilfordii in proportion, after the alcohol extraction with step (1) gained, residue merges,
The water reflux, extract, of 8-12 times of volume of addition 3 times, each 2 hours, united extraction liquid, obtain extracting solution B；
(3) take 5-fluorouracil, TPGS and phospholipid, add ethanol, ultrasonic dissolution, while stirring
Being added dropwise in distilled water, then under the conditions of 2000-4000r/min, ice bath disperses 2-4 minute, obtains dispersion liquid；
(4) merging said extracted liquid A and extracting solution B, be then slowly added into above-mentioned dispersion liquid, 1000-2000r/min stirs 5-10
Minute, concentrate, dry, pulverize, standby, obtain described Chinese medicine composition.
Treat the preparation method of the compound traditional Chinese medicine composite of colon cancer the most according to claim 4, it is characterised in that in described
Drug composition conventionally makes solid preparation.
Treat the preparation method of the compound traditional Chinese medicine composite of colon cancer the most according to claim 5, it is characterised in that described solid
Body preparation is granule, powder, tablet, pill or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610776067.3A CN106237032A (en) | 2016-08-29 | 2016-08-29 | A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610776067.3A CN106237032A (en) | 2016-08-29 | 2016-08-29 | A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106237032A true CN106237032A (en) | 2016-12-21 |
Family
ID=58079910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610776067.3A Pending CN106237032A (en) | 2016-08-29 | 2016-08-29 | A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106237032A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537146A (en) * | 2008-03-19 | 2009-09-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating carcinoma of colon |
-
2016
- 2016-08-29 CN CN201610776067.3A patent/CN106237032A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537146A (en) * | 2008-03-19 | 2009-09-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicine for treating carcinoma of colon |
Non-Patent Citations (2)
| Title |
|---|
| 王珂等: "结肠癌患者术中联合留置消癌平注射液与5-氟脲嘧啶缓释剂的疗效观察", 《实用老年医学》 * |
| 隋华等: "益气复生方联合5-Fu对人结肠癌多药耐药裸鼠皮下移植瘤的抑制作用", 《上海中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028812B (en) | Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and preparation method thereof | |
| CN106421633A (en) | Pharmaceutical composition for treating Hashimoto's thyroiditis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN101716318B (en) | Traditional Chinese medicine preparation for treating tumor of digestive system | |
| CN102600423A (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN107375815A (en) | A kind of Chinese medicine for treating tumor in digestive tract | |
| CN104825944A (en) | Drug for treating blood-heat psoriasis and preparation method thereof | |
| CN104524441A (en) | Traditional Chinese medicine composition for treating fatty liver hepatitis complicated with hyperlipidemia and preparation method thereof | |
| CN109820943A (en) | A kind of strong medicine preparation and preparation method thereof for treating gout | |
| CN106237032A (en) | A kind of compound traditional Chinese medicine composite treating colon cancer and preparation method thereof | |
| CN102225182B (en) | Traditional Chinese preparation capable of inhibiting tumor and enhancing immunity and preparation method thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN104324083A (en) | Pharmaceutical composition for treating kidney stones and preparation method of pharmaceutical composition | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN104127684B (en) | Traditional Chinese medicine compound preparation for treating cancers | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103285217B (en) | Traditional Chinese medicine for soothing liver and detoxifying | |
| CN105833220B (en) | A kind of Chinese medicine composition and purposes assisting in the treatment of gynecologic malignant tumor | |
| CN104027447A (en) | Traditional Chinese medicine for treating cancer | |
| CN104857422B (en) | It treats the composition of colorectal cancer and is used to prepare the purposes for the treatment of large intestine cancer drug | |
| CN102940674B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN103800361B (en) | A kind of treat inflammatory bowel pharmaceutical composition and preparation method and purposes | |
| CN115105576B (en) | Traditional Chinese medicine composition for treating ovarian cancer, traditional Chinese medicine preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |